These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1972445)

  • 1. Low-dose regimen of interleukin-2 for metastatic renal carcinoma.
    Sleijfer DT; Janssen RA; Willemse PH; Martens A; de Leij L; de Vries EG; Mulder NH
    Lancet; 1990 Jun; 335(8704):1522-3. PubMed ID: 1972445
    [No Abstract]   [Full Text] [Related]  

  • 2. Myositis following treatment with high dose interleukin-2 for malignancy.
    Finger DR; Plotz PH; Heywood G
    J Rheumatol; 1995 Nov; 22(11):2188. PubMed ID: 8596171
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
    Bain C; Merrouche Y; Puisieux I; Blay JY; Negrier S; Bonadona V; Lasset C; Lanier F; Duc A; Gebuhrer L; Philip T; Favrot MC
    Br J Cancer; 1997; 75(2):283-6. PubMed ID: 9010039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
    Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
    Dutcher J
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
    Muhitch JB; Schwaab T
    Immunotherapy; 2014; 6(9):955-8. PubMed ID: 25341116
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
    Kahl C; Hilgendorf I; Freund M; Casper J
    Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldesleukin for metastatic renal cell carcinoma?
    Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
    Simonelli C; Talamini R; Bearz A; Berretta M; Spazzapan S; Monini P; Sgadari C; Sartor I; Ensoli B; Tirelli U
    Ann Oncol; 2006 Aug; 17(8):1335-6. PubMed ID: 16569648
    [No Abstract]   [Full Text] [Related]  

  • 11. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.
    Abrams JS; Rayner AA; Wiernik PH; Parkinson DR; Eisenberger M; Aronson FR; Gucalp R; Atkins MB; Hawkins MJ
    J Natl Cancer Inst; 1990 Jul; 82(14):1202-6. PubMed ID: 2194036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal-cell carcinoma.
    Vincenzi B; Santini D; Tonini G
    N Engl J Med; 2006 Mar; 354(10):1095-6; author reply 1095-6. PubMed ID: 16528812
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
    Harshman L; Srinivas S
    Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
    [No Abstract]   [Full Text] [Related]  

  • 15. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2.
    Sparano JA; Brandt LJ; Dutcher JP; DuBois JS; Atkins MB
    Ann Intern Med; 1993 Apr; 118(8):617-8. PubMed ID: 8452327
    [No Abstract]   [Full Text] [Related]  

  • 16. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
    [No Abstract]   [Full Text] [Related]  

  • 18. Of snails and holy grails..
    Yang JC
    Cancer J Sci Am; 1997; 3(3):142-3. PubMed ID: 9161778
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
    Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.